Pemetrexed Maintenance Therapy Following Bevacizumab-Containing First-Line Chemotherapy in Advanced Malignant Pleural Mesothelioma

Jing, Xuquan; Zhou, Lei; Sun, Xuejun; Yu, Jinming; Meng, Xue

doi:10.1097/md.0000000000003351

Cited by 7 publications

(3 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Outcomes such as progression free survival and treatment response rates were not abstracted in this study. However, progression-free survival benefit and tolerability profile were the most cited reasons for prescribing pemetrexed as 1 L-M. A small number of studies have found that pemetrexed monotherapy was safe and effective (overall survival and time to progression) in MPM [18,[21][22][23], although progression-free survival benefits were not found in a recent study [24].…”

Section: Discussionmentioning

confidence: 99%

Malignant pleural mesothelioma: treatment patterns and humanistic burden of disease in Europe

et al. 2022

View full text Add to dashboard Cite

Background Malignant pleural mesothelioma (MPM) is an aggressive and rare tumour with poor prognosis. Most patients are diagnosed with advanced disease and there is a paucity of data on the humanistic burden of MPM in terms of impact on health-related quality of life (HRQoL) and activity. This study examined real-world treatment patterns and humanistic disease burden of MPM in Europe. Methods Physicians abstracted demographic/clinical characteristics and treatment data from MPM-patient medical records; MPM patients self-completed a questionnaire including symptoms, 3-level-EQ-5D questionnaire and Visual Analogue Scale (VAS), Lung Cancer Symptom Scale for Mesothelioma (LCSS-Meso), and Work Productivity and Activity Impairment (WPAI) questionnaire. Results Physicians (n = 171) abstracted data of 1390 patients; 767/1390 patients self-completed questionnaires. Patients were elderly with advanced, unresectable MPM. Treatment patterns followed guidelines with most (81%) patients receiving platinum+antifolate chemotherapy at first line (1 L). Maintenance treatment use was high (51.1%) despite no recommended maintenance therapies. Symptom burden was high and health states and HRQoL were poor at 1; declining further with progression. Overall mean (SD): LCSS-Average Symptom Burden Index score was 48.8 (19.3; n = 758); EQ-5D Utility Index score was 0.510 (0.349; n = 763); EQ-5D VAS score was 54.2 (20.3;n = 766); LCSS-3-Item Global Index score was 143.2 (64.5; n = 762); LCSS-normal activities score was 51.9 (24.6;n = 765); WPAI-activity impairment was 56.0% (23.2%; n = 737). Conclusion The humanistic burden of MPM is high, despite treatments being prescribed as per available guidance. Treatments that delay progression and provide palliation of symptoms are most likely to improve/maintain HRQoL.

show abstract

Section: Discussionmentioning

confidence: 99%

Malignant pleural mesothelioma: treatment patterns and humanistic burden of disease in Europe

et al. 2022

View full text Add to dashboard Cite

show abstract

“…O exemplo do estudo realizado em 2010 na Grã-Bretanha estimou 2.040 casos de mortes por mesotelioma para o ano de 2016, e nesta região as mortes poderão ocorrer até o ano de 2050 (33) . Estudos estão sendo realizados para detecção precoce e tratamento para melhores resultados no mesotelioma (37) . O diagnóstico tardio torna o prognostico ruim, com média de sobrevida de 12 meses (36) .…”

Section: Discussionunclassified

Impacto Da Exposição Ao Amianto Na Saúde Da População Adulta: Revisão Integrativa

2016

View full text Add to dashboard Cite

Objetivou-se identificar o impacto da exposição ao amianto na saúde da população adulta, nas publicações científicas. Revisão Integrativa de literatura realizada em bases de dados na área da saúde no período de 2005 a 2015. Foram selecionados 15 estudos. Verificou-se o impacto da exposição ao amianto na população adulta com o adoecimento por mesotelioma maligno, asbestose, câncer de pulmão, entre outros; a mortalidade por mesotelioma em trabalhadores conferiu prevalência significativa para o estudo. A taxa mortalidade é preocupante, haja visto que as possibilidades terapêuticas são limitadas. O impacto do amianto ultrapassa os aspectos biológicos, trazendo alterações psicoemocionais significativas na saúde da população. Destaca-se a importância do debate sobre o impacto do amianto na saúde do adulto, principalmente no campo da saúde do trabalhador sobre a necessidade do banimento de seu uso nos países que o mantém em escala industrial e comercial.

show abstract

“…Our best efforts with multimodal therapy may extend this outcome by mere months, further emphasizing the extreme need for improved therapies. Current therapeutic strategies for MPM include surgery, radiation, chemotherapy, and more recently targeted therapy and immunotherapy [ 25 - 31 ]. Table 1 summarizes the mainstays of treatment and the benefit of traditional therapies over systemic chemotherapy.…”

Section: Current Therapiesmentioning

confidence: 99%

Current and Emerging Therapy for Malignant Pleural Mesothelioma: Focus on CD26/Dipeptidyl Peptidase IV as a Therapeutic Target

Doonan

Ohnuma

Dang

et al. 2017

CCTR

View full text Add to dashboard Cite

Background: Malignant mesothelioma is a largely incurable disease that is refractory to current therapies. CD26 is a multifunctional cell surface protein involved in autoimmune disease, diabetes, and cancer. It has a role in T cell function, extracellu-lar protein modification, as a prognostic factor for cancer, and as a therapeutic target for malignant mesothelioma. New treatment strategies are urgently needed for malig-nant pleural mesothelioma (MPM), and CD26-targeted therapy represents a novel ap-proach.Outline: In this review, the most current and up-to-date literature available was reviewed and the current state of malignant mesothelioma treatment is described. Throughout the review the need for new therapeutic approaches is highlighted in the shortcomings of current therapy. CD26 is a target that is fit to take on these shortcom-ings. In this review we discuss the structure and function of CD26, its role in malignant mesothelioma and the future of anti-CD26 therapy as a versatile immunotherapeutic option.Conclusion: This review highlights the areas of most promise in treating MPM, these in-clude immune checkpoint blockade, passive immunization, and based on our recently published data, targeting of CD26 with its specific mAb. Finally we describe how the an-ti-CD26 mAb YS110 was recently evaluated in the first-in-human phase I clinical trial, showing prolonged disease stabilization and a favorable side effect profile. Through better understanding of CD26, new pathways to treating and potentially curing malig-nant mesothelioma may be discovered.

show abstract

Pemetrexed Maintenance Therapy Following Bevacizumab-Containing First-Line Chemotherapy in Advanced Malignant Pleural Mesothelioma

Cited by 7 publications

References 34 publications

Malignant pleural mesothelioma: treatment patterns and humanistic burden of disease in Europe

Malignant pleural mesothelioma: treatment patterns and humanistic burden of disease in Europe

Impacto Da Exposição Ao Amianto Na Saúde Da População Adulta: Revisão Integrativa

Current and Emerging Therapy for Malignant Pleural Mesothelioma: Focus on CD26/Dipeptidyl Peptidase IV as a Therapeutic Target

Contact Info

Product

Resources

About